InflammX Clinical Strategy

 Intermediate age related macular degeneration

• iAMD is the precursor to Geographic Atrophy (GA) at which point there is significant vision loss

• The goal of treating iAMD patients with Xiflam™ at this early stage, is to prevent patients with good vision from progressing to severe vision loss and blindness.

• InflammX is the first company with an FDA accepted Phase 2B trial design and endpoint for iAMD.

• A 300 patient Phase 2B Clinical Trial with Xiflam™ will be conducted with solely US based sites.

• Xiflam™ is supported by a clinical safety database of >2000 patients

• Oral administration significantly increases the provider base (to general ophthalmologists, optometrists etc.) since the current state of intra ocular injections remains overwhelmingly the domain of retinal specialists.

• Expanding the provider base ensures a significant expansion of care for this unmet need and a significant shift in health equity for this blinding disease.